文献速递妇科肿瘤

新辅助化疗降低宫颈癌调节性T细胞

Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer.
PubMed 文献 · Eur J Cancer · 2026-08-09

本研究分析EORTC 55994试验中64例FIGO 2009 IB2-IIA2期宫颈癌患者组织样本,采用多重免疫组化定量淋巴细胞亚群。发现含铂新辅助化疗后基质和瘤内Treg密度显著下降,治疗后增殖性Treg比例低者总生存更好。

要点

  • 含铂新辅助化疗后宫颈癌基质和瘤内Treg密度显著降低。
  • 治疗后增殖性Treg比例低与更好的总生存相关。
  • 结果提示新辅助化疗后免疫微环境变化值得进一步研究免疫治疗时机。

核心结论

  • 新辅助化疗可能减轻宫颈癌肿瘤微环境中Treg介导的免疫抑制。
  • 治疗后低增殖性Treg患者生存更有利,结果具有假设生成性。

研究设计与样本

  • 分析EORTC 55994试验中64例FIGO 2009 IB2-IIA2期宫颈癌患者组织样本。
  • 基线活检55例和治疗后手术标本43例,采用多重免疫组化及ImmuNet平台定量细胞密度。

主要发现

  • 新辅助化疗后Treg密度在基质区显著下降(p < 0.0001),瘤内区域亦显著下降(p = 0.0007)。
  • 治疗后增殖性Treg比例较低与更好的总生存相关(p = 0.018)。
  • 其他淋巴细胞亚群变化较不一致。

临床怎么用

  • 宫颈癌含铂新辅助化疗后Treg减少,提示后续免疫治疗时机可能需要考虑化疗后的免疫微环境变化。
  • 治疗后增殖性Treg比例或可作为生存相关免疫指标进一步研究。

局限性

  • 结果为假设生成性,需进一步研究验证。
  • 基线活检55例与治疗后手术标本43例数量不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The tumor microenvironment (TME) in cervical cancer may undergo immunological changes during neoadjuvant chemotherapy (NACT). The primary aim of this study was to elucidate changes in the TME of cervical cancer during platinum-containing NACT and to evaluate whether these immunological changes correlated with survival. Characterizing these changes may help identify the optimal timing for future integration of immunotherapy. This study examined alterations in lymphocyte subsets in patients with FIGO 2009 stage IB2-IIA2 cervical cancer treated with cisplatin-based NACT. METHODS: Tissue samples from 64 patients enrolled in EORTC trial 55994 were analyzed. Baseline biopsies (n = 55) and post-NACT surgical specimens (n = 43) underwent multiplex immunohistochemistry with fluorescent labels to quantify B cells, CD8 and helper T-cells, regulatory T-cells (Tregs), and tumor cells. Proliferation was assessed using Ki67 expression. ImmuNet, a validated machine-learning-based image analysis platform, was used for cell identification and density measurements. FINDINGS: Following NACT, Treg density significantly decreased in stromal (p < 0.0001) and intratumoral regions (p = 0.0007). A lower proportion of proliferating Tregs after treatment was associated with better OS (p = 0.018). Changes in other lymphocyte subsets were less consistent. INTERPRETATION: NACT appears to reduce Treg-mediated immunosuppression in the cervical cancer TME. Patients with low post-treatment Treg proliferation demonstrated more favourable survival. These findings are hypothesis-generating and suggest that the immune microenvironment following NACT warrants further investigation, including studies evaluating the optimal timing of immunotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Meek JM, van Luijk IF, Gorris MAJ, et al. Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer. Eur J Cancer. 2026. PMID: 42600508. doi:10.1016/j.ejca.2026.116984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。